Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Testing Identifies High-Risk Subtype of Acute Lymphoblastic Leukemia

By LabMedica International staff writers
Posted on 09 Dec 2016
Acute lymphoblastic leukemia (ALL) is less common in adults than in children, but adults are far less likely to survive. Adults make up about 40% of the estimated 6,590 new cases of ALL identified annually in the USA.

A high-risk subtype of acute lymphoblastic leukemia first identified in children is highly prevalent in adults with ALL and is associated with a poor outcome, but affected patients may benefit from treatment with available medications.

A large team of scientists collaborating with their colleagues at the St. Jude Children's Research Hospital (Memphis, TN, USA) studied leukemia samples from banked material obtained at diagnosis from 909 patients with precursor B-cell ALL (B-ALL), 798 of whom had suitable material for genomic analysis. The cohort was divided into the following three age groups: 344 young adults age 21 to 39 years; 304 adults, age 40 to 59 years, and 150 older adults, age 60 to 86 years.

Gene expression profiling was performed at 798 ribonucleic acid (RNA) samples using either U133 Plus 2.0 microarrays or a 15-gene Taqman quantitative reverse transcriptase polymerase chain reaction (PCR) low-density array (LDA) that identifies the Philadelphia chromosome-like (Ph-like) ALL gene signature, P2RY8-CRLF2, BCR-ABL1, ETV6-ABL1, TCF3-PBX1, and DUX4/ERG-deregulated ALL. Transcriptome sequencing (RNA-seq) was performed using the TruSeq library preparation on the HiSeq 2000 platform.

The scientists found that 194 patients, almost 25%, had the high-risk subtype Philadelphia chromosome-like ALL (Ph-like ALL). Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of young adults, 20.4% of adults and 24.0% of older adults. Overall, patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non–Ph-like ALL. Eleven new kinase rearrangements were identified, including four involving new kinase or cytokine receptor genes and seven involving new partners for previously identified genes. Many patients had genetic changes that suggest they may be treatable with targeted agents known as tyrosine kinase inhibitors which are already widely used to treat other types of leukemia that are common in adults.

Kathryn Roberts, PhD, the first author of the study said, “Our comprehensive sequencing showed that Ph-like ALL in adults is the most genetically diverse subtype of leukemia that has been described. Cumulatively more than 50 different chromosomal rearrangements involving 15 different kinases and cytokine receptors have been identified. In this study, we identified 11 chromosomal rearrangements that are new to Ph-like ALL.” The study was published in the November 2016 issue of the Journal of Clinical Oncology.

Related Links:
St. Jude Children's Research Hospital


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.